Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,067 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,060
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 399
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Type 1 Diabetes132
- Rheumatoid Arthritis131
- Atopic Dermatitis122
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections105
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California498
- Maryland198
- Alabama178
- Florida151
- Arizona150
- Massachusetts118
- New York114
- Texas112
- Illinois84
- Colorado81
Recruiting studies6,067 total
- NCT05952024RecruitingPhase 2
Acalabrutinib plus rituximab for older untreated DLBCL
This trial studies the combination of acalabrutinib and rituximab in older or frail people with newly diagnosed DLBCL (a type of lymphoma). It aims to see how well this treatment works and how safe it is for people who may not be able to tolerate standard chemotherapy.
Berkeley, CaliforniaAges 65–99 - NCT05961592RecruitingPhase 1
Study drug R-2487 for people with active rheumatoid arthritis
This Phase 1 study tests how the drug R-2487 behaves in the body and looks at early safety in adults with active rheumatoid arthritis. If you have ongoing joint inflammation despite standard treatments, this trial may offer a chance to try an investigational therapy under close monitoring.
San Diego, CaliforniaAges 18–75 - NCT05951777RecruitingPhase 2
Stem cells from your own fat for chronic brain injury
This trial tests whether stem cells taken from your own fat and given through an IV can help people with long-term brain damage from a head injury. It is for adults who have not gotten better with standard treatments.
Houston, TexasAges 18–55 - NCT05966467Recruiting
Patient registry for AQP4+ neuromyelitis optica on C5 inhibitors
This registry collects health and relapse information from adults with AQP4-positive NMOSD who are taking C5-blocking medicines to prevent long-term relapses. It helps researchers better understand treatment patterns and outcomes in real-world care.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05667701RecruitingPhase 2
Soy supplement for babies at high risk of asthma
This Phase 2 study tests whether daily soy isoflavones can lower the chance of asthma or wheezing problems in babies who are at high risk. You would join because your baby has risk factors (family history and certain genetics) and receives the study soy product.
Chicago, IllinoisAges 2 months–1 year - NCT05927454Recruiting
RaDiCo Acostill study for inflammatory fevers and arthritis
This is a long-term study that collects health information and lab samples from people who have certain diagnoses of recurring (coming and going) inflammatory fevers and related joint or immune conditions. It may help researchers better understand these diseases and how they work over time.
Paris, Île-de-France RegionAges Any age - NCT05912517RecruitingPhase 3
Nipocalimab for high-risk pregnancy blood disease
This Phase 3 trial tests nipocalimab (an antibody medicine) to help prevent severe blood breakdown in a baby when a parent has certain blood antibodies. It enrolls people who previously had severe hemolytic disease in a past pregnancy and who are currently early in pregnancy with the same risk antibodies.
La Jolla, CaliforniaAges 18–45 - NCT05927571RecruitingPhase 1
Cevostamab and elranatamab combination study for relapsed myeloma
This Phase 1 trial tests whether combining two targeted antibody medicines—cevostamab and elranatamab—is safe and whether it shows signs of activity in people whose multiple myeloma has come back or not responded. It’s early-stage, so the main goal is safety, dosing, and how the medicines behave in the body.
Camperdown, New South WalesAges 18 years+ - NCT05925452Recruiting
Genalumab for children with active systemic juvenile arthritis
This trial studies whether a medicine called genalumab can reduce inflammation and improve symptoms in children with active systemic juvenile idiopathic arthritis (sJIA). It also checks how safe the treatment is, including possible side effects.
Beijing, BenjingAges 2–17 - NCT05919511Recruiting
Questionnaire study for people at risk after stem cell transplant
This observational study follows people who had a stem cell transplant a few months ago to better understand risk for chronic graft-versus-host disease. You won’t get a study treatment; instead, you’ll complete questionnaires over time, and the study team looks at your symptoms and experiences.
Birmingham, AlabamaAges 18 years+ - NCT05940272Recruiting
Communication training for doctors treating large B-cell lymphoma
This study tests a communication training program for providers who care for people with large B-cell lymphoma. The goal is to improve how clinicians talk with patients, especially during difficult treatment periods like relapse.
New York, New YorkAges 18 years+ - NCT05934084Recruiting
Lifestyle plan for heart and health after lymphoma remission
This trial tests a structured lifestyle and survivorship care plan for people who finished treatment for certain lymphoma types and are now in long-term remission. The goal is to support long-term health (including heart-related monitoring) and reduce future risks.
Ancona, AnconaAges 18–50 - NCT05921253RecruitingEarly Phase 1
Check a brain-heart device to reduce chemo heart risk
This early-phase study tests a “neuromodulation” device (stimulating nerves that may affect the heart and blood vessels) to help lower cardiovascular risks after certain cancer chemotherapy. It may be most relevant if you recently had an anthracycline-based treatment and also have other heart-risk factors.
Oklahoma City, OklahomaAges 18–99 - NCT05934305Recruiting
Help for shame and stigma in HIV and substance use
This study tests whether a program can reduce shame and stigma for people living with HIV who also have a substance use disorder. It may help you feel less judged and cope better, while supporting HIV care.
Miami, FloridaAges 18 years+ - NCT05917210Recruiting
Peer support for TB and HIV treatment in Uganda
This trial tests a peer-led education and counseling program to help people with TB and HIV stick with their treatment. It may help improve understanding, motivation, and day-to-day adherence to medications.
KampalaAges 18 years+ - NCT05928169Recruiting
Tracking how inflammatory skin conditions change over time
This study looks at what affects the “path” (trajectory) of long-lasting inflammatory skin conditions. It may help researchers understand why symptoms change and how treatments or factors influence those changes.
KielAges birth–80 years - NCT05934448RecruitingPhase 2
CAR T plus pembrolizumab for relapsed lymphoma after prior treatment
This Phase 2 trial studies CAR T-cell therapy combined with pembrolizumab for certain hard-to-treat lymphomas that have come back or did not respond. It aims to improve tumor response and outcomes after you’ve already tried standard treatments.
Boston, MassachusettsAges 18 years+ - NCT05922501RecruitingPhase 2
Test four medicines for relapsed multiple myeloma
This Phase 2 study tests a combination of medicines (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) for multiple myeloma that has come back or did not respond to prior treatment. It may help by better controlling the myeloma after standard therapies have failed.
Boston, MassachusettsAges 18 years+ - NCT05923216Enrolling by invitation
Testing oral sesame treatment to reduce severe reactions
This study tests an oral (mouth) sesame treatment designed to help the body stay “unresponsive” to sesame after treatment. If you previously took part in the earlier sesame study, this trial may help you see whether a sustained tolerance can be achieved and maintained.
WarsawAges 4–17 - NCT05929612RecruitingPhase 2
Low-dose targeted radiation alone for marginal zone lymphoma
This Phase 2 study tests whether very low-dose radiation (adjusted based on how you respond) can treat marginal zone lymphoma without adding other medicines at first. It may help some people by reducing radiation exposure while still controlling the cancer.
Houston, TexasAges 18 years+ - NCT05923970Recruiting
MMRV vaccine booster in pregnant adults in Alberta
This study looks at whether getting a third dose of the MMRV vaccine during pregnancy is helpful. It focuses on pregnant women who were screened for rubella immunity during routine prenatal testing.
Edmonton, AlbertaAges 18 years+ - NCT05934149Recruiting
Lupus health registry that stores samples for future research
This study keeps a long-term record of people with lupus (systemic lupus erythematosus) and collects samples so researchers can study the disease better. You may be able to join if you meet lupus diagnosis criteria, are not pregnant, and can follow the study visits and consent process.
Birmingham, AlabamaAges 18–110 - NCT05932680RecruitingPhase 2
Continue teclistamab for a limited time in responding patients
This Phase 2 trial looks at stopping or limiting teclistamab after you’ve already had a good ongoing response. It aims to see if people can safely continue to benefit while using the medicine for a shorter time.
Little Rock, ArkansasAges 18 years+ - NCT05941559Enrolling by invitation
EMDR therapy for long-term rheumatoid arthritis pain
This trial tests whether eye-movement therapy (EMDR) can reduce long-lasting pain in people with rheumatoid arthritis (RA). You may be eligible if your RA has been relatively stable, your pain is still high, and you can take part in therapy sessions safely.
Enschede, OverijsselAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,067 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,241 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.